- Elucidata, founded in 2015 and headquartered in San Francisco, is a Series A company specializing in AI and cloud-based data analytics tools for life sciences research, focusing on transforming complex biomedical R&D workflows into actionable insights.
- In the past year, Elucidata raised $22.7 million in funding and launched AI Labs aimed at solving challenges in biomedical AGI, enhancing their capabilities in computational research.
- The company has formed strategic partnerships with Auron Therapeutics to advance cancer therapy and with Sapien Biosciences to convert biobank assets into AI-ready data products, leveraging extensive patient data for drug discovery.
- Elucidata's ideal buyers are organizations in the life sciences sector looking to streamline drug discovery processes and improve patient outcomes through advanced data analytics and AI solutions, making it a critical player in the evolving landscape of precision medicine.
Elucidata's workforce is organized across six departments, with a total headcount of 148 employees. The largest departments include Information Technology with 7 employees, Operations with 6, and Engineering also with 6. The Executive and Community and Social Services departments each comprise 4 employees, while the remaining departments account for 6 employees collectively. This distribution indicates a balanced functional mix, supporting both technical and operational needs.
The company operates across five locations, with a notable concentration in San Francisco, California. Each of the other locations, including Corvallis, OR, San Diego, CA, Philadelphia, PA, and Jacksonville, FL, has a single employee, contributing to a diverse geographic footprint. The 'Other' category, encompassing 28 employees, suggests a significant remote or distributed workforce, enhancing operational flexibility and talent acquisition across various regions.
